Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Papanek Julie Grant net worth and biography

Papanek Grant Biography and Net Worth

Director of Day One Biopharmaceuticals

Julie Grant is a General Partner at Canaan, a tech and healthcare venture capital fund with $5B assets under management. She primarily leads investments and company formation efforts in biopharmaceuticals. Julie is a co-founder at Day One, was previously CEO, and is chair of the board. Since joining Canaan in 2013, Julie has incubated, financed, and supported investments in multiple new ventures including Nocion, Synthekine, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), Unchained Labs, Chrono Therapeutics, Genome Medical, Glooko, Vineti, and Truveris. Prior to joining Canaan, Julie worked at Genentech in multiple capacities across development and commercial. She earned a BS in Molecular Biophysics and Chemistry from Yale, an MPhil BioScience Enterprise from Cambridge, and MBA from Stanford.

What is Papanek Julie Grant's net worth?: The estimated net worth of Papanek Julie Grant is at least $5.62 million as of September 2nd, 2022. Ms. Grant owns 439,358 shares of Day One Biopharmaceuticals stock worth more than $5,619,389 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Grant may own. Learn More about Papanek Julie Grant's net worth.
How do I contact Papanek Julie Grant?: The corporate mailing address for Ms. Grant and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at [email protected]. Learn More on Papanek Julie Grant's contact information.
Has Papanek Julie Grant been buying or selling shares of Day One Biopharmaceuticals?: Papanek Julie Grant has not been actively trading shares of Day One Biopharmaceuticals during the last quarter. Most recently, Papanek Julie Grant sold 5,000 shares of the business's stock in a transaction on Friday, September 2nd. The shares were sold at an average price of $23.82, for a transaction totalling $119,100.00. Following the completion of the sale, the director now directly owns 439,358 shares of the company's stock, valued at $10,465,507.56. Learn More on Papanek Julie Grant's trading history.
Who are Day One Biopharmaceuticals' active insiders?: Day One Biopharmaceuticals' insider roster includes Samuel Blackman (Insider), and Papanek Grant (Director). Learn More on Day One Biopharmaceuticals' active insiders.
Are insiders buying or selling shares of Day One Biopharmaceuticals?: During the last twelve months, insiders at the sold shares 27 times. They sold a total of 351,808 shares worth more than $5,688,629.99. The most recent insider tranaction occured on December, 10th when insider Samuel C Blackman sold 30,000 shares worth more than $399,300.00. Insiders at Day One Biopharmaceuticals own 8.4% of the company. Learn More about insider trades at Day One Biopharmaceuticals.
Information on this page was last updated on 12/10/2024.

Papanek Julie Grant Insider Trading History at Day One Biopharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/2/2022	Sell	5,000	$23.82	$119,100.00	439,358
8/4/2022	Sell	5,000	$20.00	$100,000.00	454,358
7/18/2022	Sell	2,600	$20.00	$52,000.00	459,358
7/8/2022	Sell	1,242	$20.00	$24,840.00	461,958
7/1/2022	Sell	1,000	$20.00	$20,000.00	464,000

Papanek Julie Grant Buying and Selling Activity at Day One Biopharmaceuticals

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Today's Range

Now: $12.79

$12.11

$13.00

50 Day Range

MA: $14.07

$12.46

$16.39

2 Week Range

Now: $12.79

$11.94

$18.07

Volume

2,277,932 shs

Average Volume

964,505 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

First JFK… next Elon?

From Porter & Company | Ad

I share with you in this special investigative documentary.

Papanek Grant Biography and Net Worth

What is Papanek Julie Grant's net worth?

How do I contact Papanek Julie Grant?

Has Papanek Julie Grant been buying or selling shares of Day One Biopharmaceuticals?

Who are Day One Biopharmaceuticals' active insiders?

Are insiders buying or selling shares of Day One Biopharmaceuticals?

Papanek Julie Grant Insider Trading History at Day One Biopharmaceuticals

Papanek Julie Grant Buying and Selling Activity at Day One Biopharmaceuticals

Day One Biopharmaceuticals Company Overview

Today's Range

50 Day Range

2 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta